Condition: PreDiabetes · Sponsor: Philip Kern
Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients
This description comes directly from the study's public registry record.
Zach Leicht · 859-218-1397 · zachary.leicht@uky.edu
Philip Kern, MD · 859-218-1394 · pake222@uky.edu
Always discuss trial participation with your own doctor first.
| University of Kentucky | Lexington, Kentucky, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04666636